Polycystic ovarian syndrome: an updated review of pathophysiology, clinical features, biomarkers, and management

Authors

  • Blessy S. Joseph Department of Pharmaceutics, St. James College of Pharmaceutical Sciences, Chalakudy, Trissur, Kerala, India
  • Dineshkumar B. Department of Pharmaceutics, St. James College of Pharmaceutical Sciences, Chalakudy, Trissur, Kerala, India
  • K. Krishna Kumar Department of Pharmaceutics, St. James College of Pharmaceutical Sciences, Chalakudy, Trissur, Kerala, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20263078

Keywords:

Polycystic ovary syndrome, Insulin resistance, Ovarian dysfunction, Biomarkers, Metabolic syndrome

Abstract

Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine and metabolic disorders affecting women of reproductive age and represents a major global public health challenge. PCOS is a heterogeneous condition characterized by reproductive dysfunction, hyperandrogenism, insulin resistance (IR), and metabolic abnormalities, frequently accompanied by psychological distress that significantly reduces quality of life. Despite its high prevalence, diagnosis, treatment, and long-term management remain challenging due to its complex, multifactorial pathophysiology. This review provides a comprehensive overview of the epidemiology, diagnostic criteria, clinical manifestations, and etiological factors associated with PCOS, with particular emphasis on genetic susceptibility, epigenetic regulation, environmental exposures, dietary habits, and lifestyle factors contributing to disease onset and progression. Key pathophysiological mechanisms are explored, including IR, hyperandrogenism, follicular arrest, chronic low-grade inflammation, oxidative stress, mitochondrial dysfunction, and adipose tissue dysregulation. The clinical manifestations of PCOS reproductive, metabolic, hyperandrogenic, and psychological along with long-term complications such as type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), endometrial disorders, infertility, and adverse pregnancy outcomes, are discussed. Emerging hormonal, inflammatory, metabolic, genetic, and molecular biomarkers are highlighted for their potential to improve diagnosis, phenotypic classification, and personalized therapy. Current treatments, including lifestyle modification, pharmacological interventions, nutritional supplementation, and emerging targeted therapies, are also summarized. A deeper understanding of the molecular mechanisms underlying PCOS is essential for enabling early diagnosis, optimizing individualized management, reducing long-term health risks, and improving outcomes through precision medicine, multidisciplinary care, evidence-based decision-making, and continued therapeutic innovation.

References

Muhas C, Nishad K, Naseef P, Vajid KA. An overview on polycystic ovary syndrome (PCOS). Technol Innov Pharm Res. 2021;6:19-30.

Tewari S, Khalua RK, Parida S. Redefining polycystic ovary syndrome (PCOS) as Polyendocrine Metabolic Ovarian Syndrome (PMOS): implications for diagnosis, pathophysiology and clinical management. Int J Gynaecol Sci. 2026;8(1):17-25.

Kaveh M, Moghadam MN, Iranpour Z, Chaichian S, Kashi AM, Afshari M, et al. Epidemiological study and clinical consequences of endometriosis and PCOS co-occurrence in a clinical population of women: a cross-sectional study. BMC Women's Health. 2026;26(1):182.

Bokka SL, Maktha VK. Impact of Polycystic Ovary Syndrome on Health-Related Quality of Life: A Cross-Sectional Study Using the PCOSQOL Scale. National J Community Med. 2026;17(03):182-6.

Koshti A, Jadeja J, Vaja M, Soni R, Yadav P, Patel D. Current Trends in the Diagnosis and Therapeutic Approaches To PCOS. J Pharmaceut Res. 2026;15(1):1243-70.

Elsayed AM, Al-Kaabi LS, Al-Abdulla NM, Al-Kuwari MS, Al-Mulla AA, Al-Shamari RS, et al. Clinical phenotypes of PCOS: a cross-sectional study. Reproduct Scie. 2023;30(11):3261-72.

Chen Y, Sun X, Xia X, Chen K, Zeng F. The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome. Front Endocrinol. 2026;16:1722649.

Zhang B, Zhou W, Shi Y, Zhang J, Cui L, Chen ZJ. Lifestyle and environmental contributions to ovulatory dysfunction in women of polycystic ovary syndrome. BMC Endocrine Disord. 2020;20(1):19.

Bruni V, Capozzi A, Lello S. The role of genetics, epigenetics and lifestyle in polycystic ovary syndrome development: the state of the art. Reproduct Sci. 2022;29(3):668-79.

Xu J, He B. The central role of hyperandrogenism in driving metabolic dysfunction in polycystic ovary syndrome: from pathophysiological mechanisms to targeted therapies. J Ovarian Res. 2026;NA

Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril. 2003;80(2):255-8.

Hu R, Jin L, Li Q, Fan P, Fan W, Xu J. Epigenetic regulation by DNA methylation in PCOS and POI: mechanisms of ovarian dysfunction and implications for clinical research. J Ovarian Res. 2026;13:123.

Shahzadi Z, Rehman L, Maryam A, Malik HA. Lifestyle Factors and Sonographic Characteristics in PCOS: A Systematic Review. Pak J Med Cardiological Rev. 2026;5(2):4248-55.

Zhang S, Jiang N, Liu G, Zhang B, Xu H, Xu Y, et al. New perspectives on polycystic ovary syndrome: hypothalamic-sympathetic-adipose tissue interaction. J Ovar Res. 2025;18(1):145.

Mu Y, Zou Y, Chen C. Knowledge, attitude and practice toward obesity and polycystic ovary syndrome among women of childbearing age with overweight or obesity. Arch Gynecol Obstet. 2026;313(1):9.

Ashraf S, Shakeel Q, Mumtaz S, Iqbal S, Afzal R, Ashraf T. Phenotypic Spectrum, Menstrual Irregularity, and Reproductive Outcomes Among Women with PCOS Attending Public Hospitals in Gujranwala: A-Participant Cross-Sectional Study. J Health Wellness Community Res. 2025;3(7):e907.

Azam SS, Vasudevan S, Bukhari WS, Thadhani J, Tasneem H, Singh S, et al. Reproductive endocrine disorders: a comprehensive guide to the diagnosis and management of infertility, polycystic ovary syndrome, and endometriosis. Cureus. 2025;17(1):10.

Magkou S, Sali E, Paschou IA, Dimopoulou SM, Tagka A, Chasapi V, et al. Skin manifestations of hyperandrogenism: an update. Hormones. 2026;1-2.

Motafeghi F, Naz MS, Tehrani FR, Behboudi-Gandevani S. Androgenetic alopecia in polycystic ovary syndrome: a cutaneous marker of systemic metabo-inflammatory and endocrine dysfunction. Endocrine Connections. 2026;15(5):10.

Alataş H, Arslan N, Keskin L, Ağralı C. Dietary Antioxidant Capacity, Inflammation, and Insulin Resistance in Women with Polycystic Ovary Syndrome: An Integrated Metabolic and Nutritional Assessment. Diabetes Metabol Synd Obesity. 2026;586793.

Pourkhani Z, Jahanian Sadatmahalleh S, Moini A, Nasiri M. The association between the follicular distribution pattern of polycystic ovaries and metabolic syndrome development in patients with polycystic ovary syndrome a prospective cohort study. Scient Rep. 2025;15(1):5284.

Bila J, Dotlic J, Andjic M, Ivanovic K, Micic J, Tulic L, et al. Obesity as a Part of Polycysric Ovary Syndrome (PCOS)-A Review of Pathophysiology and Comprehensive Therapeutic Strategies. J Clin Med. 2025;14(16):5642.

Adamczak A, Głowińska A, Banaszewska B, Wysocka E, Remlinger-Molenda A. Psychological aspects of polycystic ovary syndrome. Neuropsychiat Neuropsychol. 2003;20(1):178-85.

Gül Ö, Akkuş M, Akkuş F. Depression, anxiety, and stress in polycystic ovary syndrome: understanding the impact of adult separation anxiety and uncertainty intolerance. BMC Women's Health. 2025;25(1):377.

Karampela AI, Druce M. The Relationship Between Polycystic Ovary Syndrome (PCOS) and Depression. Clin Endocrinol. 2026;105(2):131-40.

Decrinis C, Hofmann K, Bitterlich N, Singer A, Tropschuh K, Lozza-Fiaco S, et al. Sleep disorders and psychological comorbidities in women with polycystic ovary syndrome-a cross-sectional study. Arch Gynecol Obstet. 2025;312(2):573-82

Ollila MM, Arffman RK, Korhonen E, Morin-Papunen L, Franks S, Junttila J, et al. Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria-a prospective population-based cohort study. Europ J Endocrinol. 2023;189(1):96-105.

Pourahmad B, Majidnia M, Saniee N, Riyahifar S, Moradi Y. Polycystic ovary syndrome with stroke, hypertension, and cardiovascular diseases: a systematic review and meta-analysis. BMC Women's Health. 2025;25(1):385.

Ollila MM, Hautakoski A, Arffman M, Morin-Papunen L, Koivikko M, Ebeling T, et al. Diabetic complications in women with type 2 diabetes and polycystic ovary syndrome. Eur J Endocrinol. 2025;192(3):202-9.

Agarwal R, Stanczyk FZ, Mandelbaum R, Paulson RJ, McGinnis LK, Winer SA. Prevalence of endometrial hyperplasia and carcinoma in women with polycystic ovarian syndrome. F and S Rep. 2025;6(3):394-8.

Hong SH, Sung YA, Hong YS, Song DK, Jung H, Jeong K, et al. The association between phenotypes of polycystic ovary syndrome and metabolic dysfunction-associated fatty liver disease. Front Endocrinol. 2025;16:1480528.

Odunvbun WO, Ukoba O, Isogun JK, Ekoh A. A systematic review of pregnancy outcomes and management in polycystic ovary syndrome. Afr J Reproduct Health. 2026;30(10):1.

Huffman AM, Rezq S, Basnet J, Romero DG. Biomarkers in polycystic ovary syndrome. Curr Opin Physiol. 2023;36:100717.

Kaleeswari G, Rajalakshmi S. Life Style Modification For PCOS: Systematic Review and Meta Analysis. Int J Innovat Res Health Sci. 2025;1(12):19-27.

Ee C, Tay CT. Pharmacological management of polycystic ovary syndrome. Aust Prescriber. 2024;47(4):109.

Andres-Montenegro N, Molina-Gutierrez S, Núñez-Murillo O. Evidence-Based Nutritional Supplementation in Polycystic Ovary Syndrome: A Comprehensive Review of Clinical Outcomes, Mechanisms, and Recommendations. BioNatura J. 2025;2(2):23.

Zhang F, Wu J, Ge L, Huang Y, Huang Y. A review of immunometabolic crosstalk in PCOS-related pregnancy loss: mechanisms and emerging therapeutic strategies. Gynecological Endocrinol. 2025;41(1):2600160.

Lotz L, Sillman J, Hund M, Di Domenico A, Buck K, Dittrich R. Validation of novel biomarkers for the detection of polycystic ovary syndrome in adolescents and young adult women-the PHOEBE study. Research Square. 2025.

Chen Y, Sun X, Xia X, Chen K, Zeng F. The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome. Front Endocrinol. 2026;16:1722649.

Parker J, Hitch V. New Challenges and Perspectives in Polycystic Ovary Syndrome. J Clin Med. 2025;14(24):8867.

Joham AE, Tay CT, Laven J, Louwers YV, Azziz R. Approach to the patient: diagnostic challenges in the workup for polycystic ovary syndrome. J Clin Endocrinol Metabol. 2025;110(7):e2298-308.

Downloads

Published

2026-08-27

How to Cite

Joseph, B. S., B., D., & Kumar, K. K. (2026). Polycystic ovarian syndrome: an updated review of pathophysiology, clinical features, biomarkers, and management. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 15(9), 3749–3758. https://doi.org/10.18203/2320-1770.ijrcog20263078

Issue

Section

Review Articles